The success of HAART has had some individuals question the value of Sangamo's (SGMO) quest for a functional cure. David Sobek, Associate Professor of Political Science at LSU is one of these.
Adam Feuerstein, B.S. in Political Science from Emory is another. This 350 page report by the FDA contains discussion of actual HAART patients and their difficulties with the current therapy.
http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm363982.pdf
Here is the current article from South Africa that ties this together:
http://www.timeslive.co.za/thetimes/2015/01/11/aids-update-arv-resistance-looms-as-40-fail-to-follow-regimen
And dwindling funding threatens the advancements made last year that have brought down the infection rate.
"We have made progress but the battle's not won. A fifth of the new infections in the world are taking place in South Africa," said Fareed Abdullah, CEO of the SA National Aids Council.
Nearly 40% of people on ARVs don't take them as instructed after three years, amounting to hundreds of thousands of people at risk of drug resistance.
No comments:
Post a Comment